CClinicalTrials.gg
Active, not recruitingNCT07337746Updated Jan 13, 2026

The Effect of Acapella and Incentive Spirometry on Blood Gases and Peak Expiratory Flow Rate After Coronary Artery Bypass Graft.

An interventional study of Incentive Spirometry therapy and Acapella therapy in Post Opeative Pulmonary Complication, sponsored by University of Baghdad. Active, not recruiting at 2 sites in Iraq. Open to participants aged 33 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by University of Baghdad · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as active, not recruiting.
  • Registered 4 months after the study started (first participant enrolled Sep 2025, registered Jan 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
33 Years to 60 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn if whether the Acapella and Incentive Spirometry have effect on Blood Gas and Peak Expiratory Flow Rate among patients undergoing Coronary Artery Bypass Graft Surgery. the main question it aims to answer is:

  • What is the most effect of using a capella versus incentive spirometry on blood gas parameters (pao2 and paco2) and Peak Expiratory Flow Rate in patient undergoing coronary artery bypass grafting?
  • is the incentive spirometry have effect on blood gases parameters and Peak Expiratory Flow Rate?
  • is the Acapella have effect on blood gas parameters and Peak Expiratory Flow Rate? Researcher will Compare the Level of Blood gases and Peak Expiratory Flow Rate between Coronary Artery Bypass Graft patients who receive Acapella and Incentive Spirometry and those who do not receive it to see if the Acapella and the Incentive Spirometry work to enhance the level of blood gases parameters and Peak Expiratory Flow Rate.

participant will take Acapella and incentive Spirometry on day before surgery and for three days after Surgery for 10-15 min for each session two times a day.

Read the detailed description

Heart disease has now been eclipsed by cardiovascular diseases as India's leading cause of mortality. The estimated worldwide disease burden surpasses the global average of 235 deaths per 100,000 people, with age-standardized CVD mortality rates of 272 per 100,000. The prevalence of coronary artery disease is on the rise throughout Southeast Asia, with India leading the way in recent years.

CABG is the median sternotomy is the method most frequently used to accomplish it. The process known as "grafting" involves taking a vein or internal mammary artery 3 and placing it both close to and far from the lesion.

The most vulnerable time following surgery is the early postoperative period. The reduction in lung function continues for several months following surgery.

In order to prevent or reduce complications including pneumonia, atelectasis, pulmonary insufficiency, sputum collection, and decreased gas exchange, chest physical therapy has traditionally been a basic part of postoperative care.

Patients undergoing CABG are commonly advised to perform breathing exercises, either with or without mechanical devices, in order to prevent or minimize lung deterioration. A variety of chest physiotherapy techniques are available. These include cough support, early mobilization, posture, incentive spirometry (IS), deep breathing exercises, respiratory muscles, and active cycle breathing techniques (ACBT).

Acapella is a vibration-driven respiratory therapy device that breaks up mucus and promotes airway secretions. It is another method that is frequently utilized. The apparatus can be utilized in any orientation, whether sitting, standing, or lying down, contingent upon the patient's breathing gravity. Acapella Selection is useful. People with lung disease and issues with their excretory system have wide airways. Easily disassembled for improvement, this device is a tremendous asset. The frequency and real resistance of this sludge remover can also be adjusted. In less than half of a natural chest physiotherapy session, patients' management times can also be completed. The Acapella device does not need to be removed by patients while they are using it.

In a variety of clinical contexts, there have been numerous papers demonstrating the benefits of alternate vibration and oscillation on lung function and air outflow. Acapella is made out of a metal bar attached to a handle and magnet, as well as an anti-weight cover. The cause of the oscillation in airflow is the occasional cessation of airflow through the plug, which breaks and repairs the magnetic attraction.

The goal of incentive spirometry is to get the patient to inhale fully, simulate unrestricted yawning or groaning, increase or maintain lung volume, and facilitate the ejection of phlegm.

As a result, the usage of practical tools to facilitate secretory discharge is increasing. Different technologies that support current physiotherapy approaches in increasing mobilization and secretory release have emerged in recent years. Written report focusing on the effectiveness of Acapella as a tool to help with secretion clearance in various lung diseases.

The adverse effects of general anesthesia, intubation, and analgesia on mucociliary clearance following surgery are well documented. When lung volumes are reduced, as they are during the postoperative period, coughing will be less effective since expiratory flow rate is directly correlated with lung volume.

In order to maintain postoperative CABG status, respiratory physiotherapy is essential. Physiotherapists utilize interventions such early mobilization, effective coughing techniques, postoperative breathing exercises, and inspiratory muscle training to promote oxygenation following open heart surgery and minimize lung volume declines and atelectasis.

02

Conditions studied

  • Post Opeative Pulmonary Complication

Keywords

  • Spirometry
  • Acapella
  • peak Expiratory Flow Rate
  • Arterial Blood Gases
03

In context

Lead sponsor

University of Baghdad is the lead sponsor of 164 studies on the registry; 66 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
33 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • A patient who is an adult admitted to the hospital for coronary artery bypass graft surgery after receiving a diagnosis of coronary artery disease.
  • Been between 33 years and 60 years old.
  • being open to taking part in the research and giving informed permission.

Exclusion criteria

Exclusion Criteria:

  • individuals having a body mass index (BMI) between 16 and 28 kg/m2.
  • patients who have asthma or COPD.
  • patients that need reintubation.
  • patients who have history of respiratory tract infection.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Acapella (oscilatory PEP)

    Experimental group will take Acapella for 10-15 minutes per session, two times per a day for 2 days before surgery and 3 days after CABG operation.

    Device: Acapella therapy

  • Experimental
    Incentive Spirometry

    Experimental group will not be exposed to Acapella and take only Incentive Spirometry for 10-15 minutes per session, 2 times per a day for 2 days before surgery and three consecutive days after CABG Surgery.

    Device: Incentive Spirometry therapy

  • No intervention
    Routin Care

    control group will not be exposed to Acapella or Incentive Spirometry and will take only routine care like breathing exercise, huffing, coughing and manual percussion

Interventions

  • DeviceIncentive Spirometry therapy

    is a device that computes the amount of air that is inspired into the lungs. By causing a piston inside the device to raise when breathing in, an incentive spirometer measures the volume of inspired air.

  • DeviceAcapella therapy

    Acapella is a vibration-driven respiratory therapy device that breaks up mucus and promotes airway secretions.

06

What researchers measure

Primary outcomes

  1. Peak Expiratory Flow Rate (PEFR)

    For improvement in expiratory airflow indicating lung function recovery

    Time frame: as baseline one day before surgery (pre-intervention) and post intervention in three consecutive days after surgery.

  2. Arterial Blood Gases (ABG)

    we see the change in Arterial Blood Gases value before and after intervention

    Time frame: as a baseline (pre-intervention) one day before surgery and three consecutive days after surgery and post-intervention.

07

Study locations

2 sites
  • Ibn AL-Betar Teaching Hospital
    Baghdad, Iraq
  • Iraqi Center of Heart Disease
    Baghdad, Iraq
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07337746
Lead sponsor
University of Baghdad
Responsible party
Bassima Amir Naji Omar Hilmi (Lecturer, University of Baghdad) — Principal investigator
First posted
Jan 13, 2026
Start date
Sep 1, 2025
Primary completion
Jul 1, 2026 (estimated)
Completion
Aug 1, 2026 (estimated)
Last update
Jan 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion